explore -WSS

explore

author：Wikipedia 2025-09-28 07:07:55 - browse：26868

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： ActiGraph execs on goal of drug approvals with digital endpoints

leisure time

WSS

Beware the threat of staffing cuts at the CDC

ProMED sees offers of support, but its future remains unclear

Liz Cheney makes 1st public comment since Trump's election interference indictments

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Hilary may become 1st tropical storm to make landfall in California in 84 years

Listen: Racing for gene therapy & a pioneering approval

focus

explore

hotspot

Peter Hotez and the public health issue of online harassment

Eye stem cell transplant could help restore vision in injured people

Medicare proposal to cover medical devices draws a mixed reaction

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Alkermes shareholders re

CVS Caremark has created a new ploy: the drug ‘rebate credit’

State Dept. review finds Biden bears some blame for Afghanistan failures

Cancer drug shortages' outsize impact on ovarian cancer patients

Supreme Court strikes down use of affirmative action

ProMED sees offers of support, but its future remains unclear

hotspot

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

The boys, now 6, who are gene therapy’s ‘edge case’ problem

ProMED sees offers of support, but its future remains unclear

Plastic surgeons increase patient psychiatric screenings

UnitedHealth increases loan offers after Change Healthcare outage

focus

focus

leisure time

leisure time